Clinical Trial Update: GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated GM-CSF and rituximab after autologous stem cell transplant in patients with relapsed or refractory follicular non-Hodgkin lymphoma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Leukine (sargramostim)
• Rituxan (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-22